Key News
1. Li Qiang signed a State Council decree promulgating the revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China".
Individual Stock News
1. Muxi Technology: Expects a net loss of 650 million to 798 million yuan in 2025, narrowing the loss by 43.36% to 53.86%.
2. Muxi Technology releases the XiSuo X series of scientific intelligent GPUs.
3. AMEC Semiconductor issues a price increase notice: price increases of 15% to 50%.
4. Guoke Microelectronics issues a price increase notice, with some products increasing by 80% starting in January.
5. Vanke A: Shenzhen Metro Group provides a loan of no more than 2.36 billion yuan.
6. Yongding Technology: Expects net profit to increase by 225.66% to 388.48% year-on-year in 2025.
7. Ganfeng Lithium: Expects net profit to increase by 153.04% to 179.56% year-on-year in 2025.
8. Shijia Photonics expects its 2025 net profit to increase by approximately 426% year-on-year, but its Q4 performance fell short of expectations.
9. Ningbo Fubang: Expects its 2025 net profit to increase by 3099.59% to 4379.43% year-on-year.
10. Aerospace Science and Technology: Expects its 2025 net profit to increase by 388.74% to 633.11% year-on-year.
11. Shennan Circuits: Expects its 2025 net profit to increase by 68%-78% year-on-year, leveraging opportunities such as the growing demand in the storage market to optimize its product structure.
12. Shunhao Shares: Its core technology, Orbital Chenguang, aligns closely with the global trend of space computing power development.
13. China Gold: Primarily engaged in the R&D, processing, retail, wholesale, and repurchase of gold jewelry, and does not possess exploration or mining rights.
14. Yingxin Development: Plans to acquire a 60% stake in Guangdong Changxing Semiconductor for 520 million yuan, with the memory chip business expected to contribute to the company's revenue growth.
15. Pien Tze Huang: The first subject was enrolled in the Phase I clinical trial of its innovative drug PZH2113 capsules. There are currently no drugs with the same indication and target in China or abroad that have been approved for marketing.
